Bayer will seek shareholder approval to raise equity capital worth close to 35% of its outstanding shares over the next three ...

While Bayer’s consumer and crop science divisions continued to slide—both in the fourth quarter and in 2024 overall—the ...

Manns said Bayer “urgently” needed to reduce its net financial debt. The consensus forecast from analysts is that, despite a radical dividend cut in 2024, debt declined by only €1.2bn to €33.3bn at ...

With the date of publication for a Critical Medicines Act fast approaching, the EU’s pharma industry is urging the Commission ...

Bayer and Hurdle have published groundbreaking research that represents a great advancement in aging research. The research introduces and validates a novel saliva-based DNA methylation biomarker ...

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related ...

Bayer now says it expects to make €3 billion ... results of the phase 3 ARASENS trial in the New England Journal of Medicine. The study showed that adding Nubeqa to standard therapy with anti ...

The company has reported the first phase 3 results in hand for gadoquatrane, which reduces the dose of gadolinium delivered during an MRI scan by around 60% compared to current macrocyclic ...

According to The Wall Street Journal, Bayer started putting in the cotton ... More from Science We've all been there: reaching for the medicine cabinet with a splitting headache, opening the ...

Prior to joining Bayer, she was Associate Professor of Medicine in the Division of Cardiology at Emory University School of Medicine and has contributed to more than150 peer-reviewed publications. She ...

A collaborative study led by Bayer and Hurdle, in partnership with top academic institutions including the University of Birmingham and the Unive ...

Bayer cut its full-year earnings target after a tough agricultural market hit its crop-science division, and said it heads ...